Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Mupadolimab · CPI-006, CPX-006

Monoclonal antibody · Antagonist of CD73 (5'-ecto-nucleotidase) (NT5E) · developed by Corvus Pharmaceuticals

Phase 3 Most advanced trial (none active)
CRVS Developer
2 Registered trials

What is Mupadolimab?

Mupadolimab is a humanized IgG1 monoclonal antibody that binds the ectoenzyme CD73 (NT5E) on tumor cells, leading to its internalization and blocking conversion of AMP to adenosine. It is being studied in multiple solid tumors and lymphoma, alone and in combination with other agents.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
CPI-006, CPX-006
Drug type
Monoclonal antibody
Targets
CD73 (5'-ecto-nucleotidase) (NT5E)
Mechanism
Antagonist of CD73 (5'-ecto-nucleotidase) (NT5E)
Pathways
adenosine-mediated immunosuppression, CTL activity, MDSC and regulatory T-lymphocyte suppression
Therapy area
Oncology
Developer
Corvus Pharmaceuticals, Inc. (CRVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
23ET6940RM

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04734873 Phase 3 Covid-19 Terminated CRVS
NCT03454451 Phase 1 Non-Small Cell Lung Cancer Completed CRVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder CancerCervical CancerColorectal CancerCovid-19Endometrial CancerMetastatic Castration Resistant Prostate CancerNon-hodgkin LymphomaNon-Small Cell Lung CancerOvarian CancerPancreatic CancerRenal Cell CancerSarcomaSquamous Cell Carcinoma of the Head and NeckTriple Negative Breast Cancer

Other drugs acting on NT5E

More from Corvus Pharmaceuticals

Sources

Updated Nov 8, 2026. Something wrong or missing? Report it on the CRVS page.

Follow CRVS, the company behind Mupadolimab

See CRVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CRVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.